

Novartis AG
Investor Relations



Sustainability-linked Bond

Investor Presentation
September 15, 2020

Disclaimer (I)

Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels)

This presentation does not constitute an offer or invitation to subscribe for or purchase any securities and nothing contained herein shall form the basis of any contract or commitment whatsoever. This presentation is being communicated in the United Kingdom only to persons that Novartis, on reasonable grounds, believe are qualified investors (as defined in Regulation (EU) 2017/1129) (i) having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “**Order**”) or falling within Article 49(2)(a) to (d) of the Order and (ii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as “**Relevant Persons**”). In the United Kingdom, this presentation is only directed at Relevant Persons and any investment or investment activity to which the presentation relates is only available to Relevant Persons or will be engaged in only with Relevant Persons. In the United Kingdom, solicitations resulting from this presentation will only be responded to if the person concerned is a Relevant Person. Other persons in the United Kingdom should not rely or act upon this presentation or any of its contents.

This presentation is being furnished to you solely for your information and may not be reproduced or redistributed to any other person. In particular, this presentation may not be taken or transmitted into the United States, Australia, Canada or Japan or distributed, directly or indirectly, in the United States, Australia, Canada or Japan. The information contained herein does not constitute or form part of an offer to sell or the solicitation of an offer to buy the securities in the United States. The securities described herein have not, and will not, be registered under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”) and may not be offered, sold or delivered within the United States or to the account of US Persons unless the securities are registered under the Securities Act, or an exemption from the registration requirements of the Securities Act is available. Investors and prospective investors in securities of the issuer mentioned herein are required to make their own independent investigation and appraisal of the business and financial condition of such company and the nature of the securities.

Any offering of any security or other financial instrument that may be related to the subject matter of this communication will be made pursuant to separate and distinct documentation (a “**Prospectus**”) and in such case the information contained herein will be superseded in its entirety by any such Prospectus in its final form. In addition, because this communication is a summary only, it may not contain all material terms and this communication in and of itself should not form the basis for any investment decision. Investors should not subscribe for any of the securities referred to in this communication other than on the basis of information contained in such Prospectus. Copies of the Prospectus and any supplements thereto will be available free of charge at Société Générale, Paris, Zurich branch, Talacker 50, 8001 Zurich, Switzerland (+41(0)58 272 34 17). No representation or warranty is given as to the accuracy or completeness of the information contained herein. There is no obligation to update, modify or amend this communication or to otherwise notify the recipient if information, opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate.

By participating in this presentation or by accepting any copy of the slides presented, you agree to be bound by the foregoing limitations.

Disclaimer (II)

This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995, that can generally be identified by words such as “strategy,” “commitment,” “initiatives,” “strive,” “target,” “aim,” “intend,” “potential,” “expected,” “will,” “planned,” “pipeline,” or similar expressions, or by express or implied discussions regarding the planned issuance of a sustainability linked bond; regarding our goals to increase the reach of our Strategic Innovative Therapies and our Flagship Programs as linked to the bond’s coupon payments; regarding our environmental, social and governance activities generally; or regarding potential new products, potential new indications for existing products, potential product launches, or regarding potential future revenues from such products; or by discussions of strategy, plans, expectations or intentions, including with respect to current, planned and potential future actions in the areas of access to medicines. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. You should not place undue reliance on these statements. In particular, our expectations could be affected by, among other things: disruptions in the EUR bond market or financial markets generally that prevent or delay the issuance of our sustainability linked bond; a failure to meet either or both of the stated targets to increase the reach of our Strategic Innovative Therapies or our Flagship Programs in the prescribed time frame; changes to our credit rating or other aspects of our business that impact our ability to comply with the terms of the bond or to repay the bond; the impact of pandemic disease such as COVID-19 on our ability to increase the reach of our Strategic Innovative Therapies or our Flagship Programs; uncertainties regarding potential significant breaches of data security or data privacy, or disruptions of our information technology systems; regulatory actions or delays or government regulation generally, including potential regulatory actions or delays with respect to the development of the programs and products described in this presentation; the potential that the strategic benefits, synergies or opportunities expected from the proposed bond transaction may not be realized or may be more difficult or take longer to realize than expected; the uncertainties in the research and development of new healthcare products, including clinical trial results and additional analysis of existing clinical data; safety, quality, data integrity, or manufacturing issues; uncertainties involved in the development or adoption of new technologies and business models; our performance on environmental, social and governance measures and our ability to achieve our environmental, social and governance goals and targets generally; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; uncertainties regarding future global exchange rates; uncertainties regarding future demand for our products; and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this presentation as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.

Harry Kirsch

Chief Financial Officer



Novartis has a strategic commitment to “building trust with society”

Over the past 20 years, Novartis has evolved its approach to corporate responsibility, moving beyond philanthropic initiatives to strategically integrating ESG aspects in its core business operations



Building trust with society is one of Novartis' 5 core strategic priorities

Our strategy on building trust with society rests upon four pillars

Pricing & Access



Global Health Challenges



Ethical Standards



Corporate Citizenship




We recently reinforced our commitment to improving patient access in LMICs

Novartis announced its **2025 Patient Access Targets** at ESG day on September 1, 2020

1 Access to Innovative Therapies




At least **200% increase** in patients reached in Low and Lower Middle Income Countries (LMICs) with **Strategic Innovative Therapies**¹ by fiscal year 2025



2 Global Health Challenges



At least **50% increase** in patients reached in LMICs with the **Novartis Flagship Programs** by fiscal year 2025



The number of patients reached with our medicines is a **core and material** key performance indicator (KPI) for Novartis (regularly reported to and monitored by the Novartis Executive Committee), **measurable on a consistent basis**² and **externally verifiable**

1. As defined in the bond's Terms and Conditions 2. See slide 16 in the Appendix

We aim to increase our strategic innovative therapies patient reach by 200% by 2025



Access to medical innovation is a **challenge** in LMICs

Patients in LMICs often do not have early and/or affordable access to innovative therapies

We have a **KPI** to measure our contribution

Novartis uses the number of patients reached with Novartis' Strategic Innovative Therapies (SITs)¹ to monitor its progress in helping to address the access to innovation challenge

We have set ourselves an ambitious **2025 Patient Access Target**


We aim to increase by at least 200% the number of patients reached with SITs in LMICs by the end of fiscal year 2025 (compared to 2019)

1. As defined in the bond's Terms and Conditions

Close collaboration with healthcare systems will be key to achieving this ambitious target

An increase of at least 200% in the number of patients reached with SITs is an ambitious target...

Annual number of patients reached with SITs in LMICs (in millions)



...but is considered achievable thanks to multiple access strategies and initiatives

Holistic approach to market access in LMICs

Developing effective **affordability strategies**

Expanding use of **emerging market brands**

Lowering distribution costs

Strengthening **health systems**

We aim to further increase our Flagship Programs' reach by 50% by 2025



Novartis Flagship Programs focus on four key global health challenges

The Novartis Flagship Programs represent an end-to-end approach to disease management for key global challenges that disproportionately affect LMICs; like **malaria** (400 000 + deaths per year worldwide with children under 5 years of age being the most vulnerable group), **sickle cell disease** (single most important genetic cause of childhood mortality globally) as well as neglected tropical diseases, such as **Chagas disease** and **leprosy**

We have a KPI to measure our contribution

Novartis uses the number of patients reached with the Novartis Flagship Programs to monitor its progress in helping address the malaria, leprosy, sickle cell disease and Chagas challenges


We have set ourselves an ambitious 2025 Patient Access Target

We aim to increase by at least 50% the number of patients reached with Novartis' Flagship Programs in LMICs by the end of fiscal year 2025 (compared to 2019)

Sources: World Health Organization (WHO), British Journal of Hematology

Numerous initiatives created across the four flagship programs to increase patient reach

Annual number of patients reached with Flagship Programs in LMICs (in millions)



The Flagship Programs have seen a **decreasing number of patients** reached in the last years...

The decrease is mainly driven by:

- Pricing challenges and generic competition in malaria access
- Significant reduction in leprosy disease prevalence, where Novartis in partnership with the WHO has provided treatment for over 7 million patients since 2000

...but with **several new initiatives**, Novartis is confident it can **increase patient numbers by at least 50%** by 2025

Sub-Saharan Africa Strategy driving increase in patient reach

Expanding reach with **malaria treatments**

Holistic approach to **sickle cell disease** treatment

Potential **new therapy** for Chagas Cardiomyopathy

AI-based approach to improve **leprosy diagnosis**

We intend to establish a direct link between our commitments and our funding strategy

Today, we announced our intention to issue Novartis' first-ever **Sustainability-linked Bond**

Use of proceeds



The bond proceeds will be used for general corporate purposes, which may include the refinancing of existing indebtedness

Coupon linked to the Group's 2025 Patient Access Targets



The bond will feature a coupon **step-up of 25 basis points**, which will be payable to investors commencing with the first interest payment date after 31 December 2025 in case Novartis fails to reach **one or both** of the Group's 2025 Patient Access Targets

Transparent reporting and verification



Novartis will publish its annual patient reach numbers, for both its Strategic Innovative Therapies and its Flagship Programs; these annual patient reach figures, plus the 2019 baseline, will be covered by a limited assurance report from an external verifier

Patient Access Targets are backed by 2nd party opinions and independent assurance



The Group's 2025 Patient Access Targets have received positive feedback from two **independent reviewers**

Novartis has obtained **two separate second party opinions**: one from the **Access to Medicine Foundation**, an independent non-profit organisation focused on access to medicine in LMICs, on the social benefits of the 2025 Patient Access Targets, and the other from **Sustainalytics**, a consultancy organization with recognized environmental, social and governance expertise, on the social benefits of the 2025 Patient Access Targets and on the alignment of this bond to the Sustainability-linked Bond Principles, published by the International Capital Markets Association (ICMA)



An external verifier has performed **limited assurance procedures** on 2019 baseline

An independent expert of international standing has prepared limited assurance reports for our baseline patient reach numbers and will also do so for our performance against the 2025 Patient Access Targets

Both, the second party opinions and the report from the external verifier, are available on Novartis' website

The bond is aligned with the ICMA's Sustainability-linked Bond Principles

In June 2020, the ICMA published the Sustainability-linked Bond Principles (SLBP), a set of voluntary process guidelines that recommend structuring, disclosure and reporting features for these type of bonds

1 Selection of KPIs

The chosen KPIs are relevant and of core importance to Novartis

3 Bond characteristics

The bond coupon increases if Novartis fails to reach one or both of the 2025 Patient Access Targets

5 Verification

Baseline and Target achievement verified by an external verifier

2 Calibration of Targets

2025 Patient Access Targets are ambitious and represent a material improvement of the underlying KPIs

4 Reporting

Novartis will publish annual reports on performance of KPIs

J.P. Morgan, one of the coordinators of the SLBPs, acts as **sustainability-linked structuring agent** for this transaction



Thank you

Transaction Overview

Issuer	Novartis Finance S.A. (Ticker: NOVNVX)
Guarantor	Novartis AG
Ranking	Senior, unsecured
Listing	SIX Swiss Exchange Listing
Expected ratings	A1 / AA- by Moody's and S&P
Tenor	8 years (September 2028)
Sustainability-linked coupon step-up	25bps commencing with first interest payment date after December 31, 2025 if Novartis fails to achieve one or both 2025 Patient Access Targets
Currency / Amount	EUR benchmark
Use of Proceeds	General Corporate Purposes, which may include the refinancing of existing indebtedness
Optional Redemption	Tax Call, after ESG report for 2025: MWC, 3-months Par Call
Sustainability-linked Bond Structuring Agent to the Issuer	J.P. Morgan
Active Bookrunners	Barclays, HSBC, J.P. Morgan, Société Générale

Our methodology to estimate patient reach is measurable and verifiable

We estimate the number of patients reached with a particular therapy in any fiscal year using a formula, based on annual product sales volumes and an assumed standard number of units of the relevant therapy used by the average patient in the relevant fiscal year

Patient reach of a particular therapy

Annual product sales volume

Annual product sales volume (in units and by country)

Volume per patient

Assumed standard number of units of the relevant therapy used by the average patient in the relevant fiscal year, based on relevant assumptions¹, including with regard to:

- Patient compliance rate
- Average daily doses per patient
- Recommended and/or average days of therapy

1. Assumptions are, in principle, global assumptions; however, in specific cases, local modifications are allowed